Teleflex’s acute care, urology, and OEM selloffs reflect an ongoing strategic shift following plans announced earlier this year to split its business in two.

Needham analysts said Teleflex’s inability to secure a price above the low end of their expectations could reflect “the continued poor performance of UroLift.” ...

Medical device maker Teleflex said on Tuesday it would sell three units for a combined $2.03 billion, as it sharpens its focus on its critical care and hospital businesses. Shares of the company were ...

Wondering if Teleflex is a beaten down opportunity or a value trap at today’s price? Let us walk through what the numbers are really saying about the stock. After sliding 3.8% over the last week, ...

The OEM arm is sold to private equity firms Montagu and Kohlberg, while UK-based Intersurgical will take over the other two divisions in $2B deal.

Teleflex Incorporated announced it has entered into definitive agreements to sell the company’s acute care, interventiona ...

Teleflex said it plans to sell three of its businesses for a total of $2.03 billion in cash as it continues to focus on its core markets.

Shares of medical technology company Teleflex (NYSE:TFX) fell 22.9% in the morning session after the company reported disappointing fourth-quarter results, with revenue missing expectations by a ...

CAUTION: Federal (USA) law restricts these devices for sale or use by or on the order of a physician.

This week's Medtech in a Minute features news about Teleflex and an update on Alcon's efforts to buy Staar Surgical amid ...

Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System as a leading minimally invasive treatment for benign ...

Teleflex stock (NYSE: TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a 31% fall this year, underperforming the broader S&P500 index, ...